申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP2179994A1
公开(公告)日:2010-04-28
The present invention provides a novel fused bicyclic compound having an affinity to a receptor of mineral corticoid (MR), shown by the formula [I]:
wherein the ring A is a benzene ring having a substituent R1, fused to an adjacent 6-membered heterocyclic ring and further optionally having a substituent(s) other than R1,
R1 is an alkylsulfonylamino group etc.,
R2 and R3 are (a) the same of different and a hydrogen atom, an alkyl group or a substituted or unsubstituted aryl group, (b) combined each other to form an oxo group or (c) combined each other at its terminal together with the adjacent carbon atom to form a cycloalkyl group,
X is a group of =N-, =C(R4)- or -CH(R4)-,
R4 is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom, (d) an alkyl group, (e) an alkenyl group, (f) a cycloalkyl group (g) an alkanoyl group, (h) a carbamoyl group or (i) a cycloalkenyl group,
Ar is an optionally substituted aromatic cyclic group and
a dotted line means presence or absence of a double bond,
or a pharmaceutically acceptable salt thereof,
which is useful as an antihypertensive agent etc.
本发明提供了一种对矿物皮质激素(MR)受体具有亲和力的新型融合双环化合物,如式[I]所示:
其中,环 A 是具有取代基 R1 的苯环,与相邻的 6 元杂环融合,还可选择具有 R1 以外的取代基、
R1 是烷基磺酰胺基团等、
R2 和 R3 (a) 相同或不同,是氢原子、烷基或取代或未取代的芳基,(b) 相互结合形成氧代基团,或 (c) 在其末端与相邻碳原子相互结合形成环烷基、
X 是 =N-、=C(R4)- 或 -CH(R4)-、
R4 是 (a) 氢原子、(b) 氰基、(c) 卤素原子、(d) 烷基、(e) 烯基、(f) 环烷基、(g) 烷酰基、(h) 氨基甲酰基或 (i) 环烯基、
Ar 是任选取代的芳香环基,且
虚线表示存在或不存在双键、
或其药学上可接受的盐、
可用作降压药等。